11 Panel Oral Swab

What Is an 11 Panel Oral Swab Drug Test?

The 11 panel oral swab drug test is a pen-style oral fluid screening device that detects eleven substances in a single non-invasive saliva collection. It occupies a precise position in the oral swab lineup as the only configuration at 12 Panel Now that makes norFentanyl (NFYL) available as a standard dedicated analyte. While every other panel tier offers fentanyl detection through a parent FEN strip, the 11 panel NFYL configuration goes one step further by detecting the primary metabolite that remains in oral fluid after fentanyl has already partially cleared. This makes it the most specific fentanyl-related detection configuration in the entire oral fluid lineup. All products carry a Forensic Use Only classification, deliver results in 5 to 10 minutes, and are available for same-day wholesale shipping starting from $1.59 per unit. According to the DOT Federal Register proposed rulemaking of September 2025, both fentanyl and norFentanyl are under active consideration as distinct mandatory testing analytes for federal transportation programs, confirming that norFentanyl is now a recognized regulatory priority at the federal level and not simply a niche clinical concern.

What Are the Two Configurations of the 11 Panel Oral Swab?

At 12 Panel Now, the 11 panel oral swab is available in two distinct configurations serving two different program populations. The norFentanyl (NFYL) configuration covers AMP, BAR, BUP, BZO, COC, MET, MTD, OPI/MOR, OXY, PCP, THC, and norFentanyl and is designed for MAT programs, Suboxone clinics, probation monitoring, and any setting where fentanyl metabolite detection is the clinical priority alongside buprenorphine compliance. The ALC configuration covers ALC, AMP, BAR, BZO, COC, MET, MTD, OPI/MOR, OXY, PCP, and a further substance, designed for transportation and compliance programs that need alcohol detection alongside the full baseline without BUP or THC in the panel. Selecting the correct configuration is the most important pre-purchase decision at this tier. The two configurations serve fundamentally different program populations and cannot be substituted once a bulk order has been placed.

What Is norFentanyl and Why Is It the Defining Analyte of the 11 Panel?

NorFentanyl is the primary metabolite produced when the human body breaks down fentanyl after ingestion. It is structurally distinct from fentanyl itself and is detected by a separate dedicated immunoassay strip at a 20 ng/mL cutoff in oral fluid. The clinical importance of this distinction is significant. Fentanyl is an extremely fast-acting synthetic opioid that clears from oral fluid within a few hours to approximately 24 hours after use. NorFentanyl persists in biological specimens slightly longer than the parent compound because it is produced downstream in the metabolic process and excreted more gradually. The 11 panel NFYL oral swab detects norFentanyl as a separate analyte from any fentanyl parent compound strip, providing a secondary fentanyl-related detection signal that extends the operational detection window for programs testing individuals with documented fentanyl use histories. The SAMHSA Drug-Free Workplace FAQ confirms that fentanyl and its metabolites require dedicated analytes and are not detected by standard opiate immunoassay strips, reinforcing why a norFentanyl-specific strip at the 11 panel tier provides meaningful additional coverage beyond what any standard or expanded OPI analyte can offer.

How Long Does norFentanyl Stay Detectable in Oral Fluid?

The detection window for norFentanyl in oral fluid extends slightly beyond the parent fentanyl compound. While fentanyl typically clears from saliva within a few hours to 24 hours depending on the dose and the individual’s metabolism, norFentanyl remains detectable for a longer period as the metabolic breakdown continues and the compound concentrates briefly before being fully excreted. The practical implication for testing programs is that a donor who used illicit fentanyl 24 to 36 hours before testing may produce a negative result on a parent FEN analyte strip while still retaining detectable norFentanyl concentrations above the 20 ng/mL threshold on the NFYL strip. For court-ordered drug testing programs where testing is conducted at intervals of 24 to 72 hours, the NFYL analyte closes a detection window that the parent FEN strip cannot reliably cover alone. Any result on the norFentanyl strip that is at or above 20 ng/mL is a presumptive positive and must be confirmed by GC-MS or LC-MS/MS laboratory testing before any compliance or legal action is taken.

Who Actually Needs norFentanyl Detection in Their Testing Program?

The norFentanyl analyte in the 11 panel oral swab is not universally necessary for every program. It is specifically valuable for three institutional populations where the fentanyl detection window gap presents a real operational risk. Programs managing patients in opioid use disorder recovery where fentanyl relapse is the highest-consequence event — particularly rehabilitation and treatment centers conducting regular monitoring — benefit from the extended detection signal that norFentanyl provides over the parent compound alone. Probation departments and drug courts whose participants have documented fentanyl histories and who are tested on scheduled intervals benefit because norFentanyl reduces the ability to time fentanyl use to fall outside the parent compound detection window before a known test date. Correctional facilities experiencing illicit fentanyl infiltration benefit because the norFentanyl metabolite window provides an incremental advantage in detecting fentanyl use that occurred outside the brief parent compound detection window. For programs whose population does not have a specific documented fentanyl exposure concern, the norFentanyl analyte provides minimal additional value over a standard FEN strip at the 10 panel tier. The decision to use the 11 panel NFYL configuration should be driven by documented population risk rather than by panel count alone.

How Does norFentanyl Detection Protect Programs Against Scheduled Testing Vulnerability?

Scheduled drug testing is significantly less effective than random or unannounced testing because donors with substance use histories can calculate when to abstain to fall below detection threshold before a known test date. Fentanyl’s very short oral fluid detection window makes it particularly susceptible to this vulnerability. A donor who knows a test is scheduled 48 hours in advance can simply abstain from fentanyl use for that window and produce a negative result on a parent FEN strip. The norFentanyl metabolite, which clears more slowly, reduces the abstinence window needed to produce a double-negative result on both the FEN and NFYL strips simultaneously. While no single analyte eliminates scheduled testing vulnerability entirely, the 11 panel NFYL configuration directly addresses the most exploitable gap in fentanyl-specific oral fluid screening. The NIJ research on fentanyl detection in court-ordered testing identifies the short detection window as the primary operational limitation of fentanyl screening in supervised populations, and the norFentanyl metabolite analyte is the most direct available response to that specific limitation in an oral fluid format.

Does the 11 Panel NFYL Configuration Work for MAT and Suboxone Programs?

Yes. The 11 panel NFYL configuration is particularly well-suited for Suboxone and buprenorphine-based MAT programs because it simultaneously provides BUP compliance monitoring at a 5 ng/mL cutoff, BZO co-occurring misuse screening, and norFentanyl detection for patients in a treatment population that has high documented fentanyl exposure risk. A buprenorphine clinic managing patients in early recovery needs to know three things at each visit: is the patient taking their prescribed Suboxone, are they using benzodiazepines that increase overdose risk, and have they been exposed to illicit fentanyl since the last visit. The 11 panel NFYL configuration answers all three questions in a single pen-style oral fluid collection administered in plain view at the clinic window without any restroom or specimen handling requirement. The BUP analyte at 5 ng/mL is calibrated to detect therapeutic doses of buprenorphine, meaning it confirms adherence rather than requiring supratherapeutic concentrations to produce a result. The SAMHSA opioid treatment program guidance identifies regular drug testing as a core component of MAT compliance monitoring, and the 11 panel NFYL configuration provides the most clinically complete single-device oral fluid option for buprenorphine-specific MAT oversight available in the lineup.

What Does the ALC Configuration of the 11 Panel Add That the NFYL Config Does Not?

The ALC configuration of the 11 panel oral swab trades BUP, BZO, and THC coverage for alcohol (ALC) detection at a 0.02% threshold, making it a fundamentally different clinical tool from the NFYL configuration. It is designed for programs where current alcohol impairment alongside comprehensive drug screening is the operational priority rather than MAT compliance. DOT-adjacent transportation employers, post-accident investigation programs, and probation supervision programs where alcohol abstinence is a documented condition of supervised release use the ALC configuration to confirm both drug and alcohol compliance simultaneously in a single ten-minute observed collection. The alcohol analyte detects ethanol in oral fluid for 12 to 24 hours following consumption, which answers the operationally relevant question of whether the donor has been drinking today rather than at some point in the past several days. For programs that need both ALC and norFentanyl in a single device, neither current 11 panel configuration provides that combination simultaneously. Programs with that dual requirement should evaluate the 12 panel oral swab configurations that include both analytes.

How Far Back Does the 11 Panel Mouth Swab Drug Test Go?

The 11 panel mouth swab drug test is optimized for detecting recent use across all eleven analytes, with detection windows ranging from 12 to 72 hours depending on the substance. Amphetamines and methamphetamine are detectable for up to 72 hours. Opiates and morphine are detectable for up to 48 hours. Oxycodone is detectable for 24 to 48 hours. Buprenorphine is detectable for 24 to 48 hours following a therapeutic dose. Benzodiazepines are detectable for up to 72 hours depending on the specific compound. Barbiturates range from 24 to 72 hours. PCP is detectable for up to 48 hours. THC has the shortest and least consistent window at 24 to 48 hours in moderate users. NorFentanyl is detectable for a window that extends slightly beyond the parent fentanyl compound. Alcohol is detectable for 12 to 24 hours. Cocaine clears quickly in oral fluid, typically within 24 hours. The SAMHSA 2024 Oral Fluid Collection Handbook requires that donors avoid placing anything in their mouth for at least 30 minutes before collection, with the administrator observing the donor throughout the waiting period. Results must be read within 5 to 10 minutes of device activation. Complete guidance is in the Saliva Test Guide.

How Accurate Is the 11 Panel Oral Swab Drug Test?

The 11 panel oral swab drug test delivers over 97% accuracy across all eleven analytes when administered correctly under standard conditions. The norFentanyl strip at 20 ng/mL uses the same lateral flow immunoassay format as all other analytes on the panel. The most common cause of inaccurate results is not product failure but rather insufficient saliva volume from failing to confirm the saturation indicator before activating the device, or the donor consuming food, drink, or mouthwash within 30 minutes before collection. The norFentanyl analyte may produce cross-reactive results at high concentrations of certain structurally similar opioid metabolites, and any presumptive positive on the NFYL strip must be confirmed by GC-MS or LC-MS/MS laboratory analysis before any clinical, legal, or compliance consequence is applied. The same confirmation requirement applies to all other analytes on the panel. A visible test line in any substance zone, however faint, is a confirmed negative. An absent test line with a present control line is a presumptive positive requiring confirmation. An absent control line invalidates the entire test and requires immediate retesting with a fresh device.

11 Panel vs. 12 Panel Oral Swab — When Is the 11 Panel the Right Choice?

The 11 panel oral swab is the right choice when a program needs norFentanyl detection within a comprehensive MAT-relevant baseline that retains BUP, BZO, and THC, and does not require the configuration variety or the CLIA Waived option that the 12 panel tier provides. Programs that need multiple distinct configurations for different population segments, a CLIA Waived product for clinical diagnostic use, or MDMA detection as a dedicated standard analyte should step up to the 12 panel. The 11 panel NFYL configuration serves a specific clinical purpose that the 10 panel cannot serve without also taking on the ketamine and propoxyphene analytes of the specialty configuration, and that the 12 panel does not replicate because norFentanyl is not a standard analyte at the 12 panel tier. For programs where the substance profile is specifically AMP/BAR/BUP/BZO/COC/MET/MTD/OPI/OXY/PCP/THC plus norFentanyl, the 11 panel is the most precise and cost-effective fit in the entire oral swab lineup.

Is the 11 Panel Oral Swab Used for Court-Ordered Drug Testing?

Yes. The Forensic Use Only classification on both 11 panel configurations makes them appropriate for court-ordered compliance monitoring, probation testing, and drug court supervision programs. The NFYL configuration is particularly relevant for justice programs managing participants with fentanyl use histories, where the norFentanyl metabolite provides a more complete fentanyl-related detection picture than the parent compound alone. Court-ordered testing programs using oral fluid already benefit from the fully observed collection format that eliminates specimen manipulation, and the NFYL analyte adds a specific layer of detection depth for the substance that represents the highest mortality risk in their supervised populations. Programs that also manage participants on buprenorphine as a condition of supervised release benefit from the BUP analyte at 5 ng/mL confirming MAT adherence at the same time as illicit substance and norFentanyl screening, all in a single collection during a regular supervision check-in visit.

Buying 11 Panel Oral Swab Drug Tests in Bulk

At 12 Panel Now, both configurations of the 11 panel saliva drug test are available at wholesale pricing starting from $1.59 per unit with same-day shipping on qualifying orders placed before 3:00 PM EST. The NFYL and ALC configurations serve different program populations and must be confirmed before placing any bulk order. We carry over 15 million products in stock across our US-based warehouse at all times with no backorders or supply gaps. Send us a competitor rate sheet and we beat it by 10% guaranteed. Store all kits between 36°F and 86°F away from direct sunlight and humidity. OEM, private label, and custom configuration orders are available for distributors, treatment networks, and multi-site compliance programs. Contact the wholesale team at 561-897-9238 or [email protected].

This page covers the 11 Panel Oral Swab Drug Test category at 12 Panel Now, located at 12panelnow.com/product-category/oral-swabs/11-panel-oral-swab/. NFYL configuration: AMP/BAR/BUP/BZO/COC/MET/MTD/OPI/OXY/PCP/THC/NFYL at 12panelnow.com/product/11-panel-pen-style-oral-fluid-drug-test-with-alc/. ALC configuration: ALC/AMP/BAR/BZO/COC/MET/MTD/OPI/OXY/PCP at 12panelnow.com/product/oral-swab-11-panel-oral-fluid-drug-test/. All products carry a Forensic Use Only classification. Wholesale shipping from 12 Panel Now, 801 N Congress Ave, Boynton Beach FL 33426. Regulatory references: SAMHSA Oral Fluid Mandatory Guidelines effective October 10, 2023. HHS fentanyl addition to federal testing panel effective July 7, 2025. DOT proposed rulemaking adding norFentanyl to DOT panel, Federal Register September 2, 2025.

Cutoff levels align with SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid, effective October 10, 2023. All presumptive positive results require GC-MS or LC-MS/MS laboratory confirmation before any consequential action.